Researchers at the New York Stem Cell Foundation have developed a technique to produce bioengineered bone grafts for large bone defects, which are currently difficult to treat using conventional techniques. To deal with bone defects, clinicians currently use either synthetic materials or bone grafts from the patient or a donor. However, these graft (Read more...)
Antibiotics suffer from eventual resistance by the bacteria and the fact that they can be quite indiscriminate in who they attack, including the gut’s healthy microbiome. But, there are also bacteriophages, which are viruses that can kill specific bacteria without harming any other bacteria. The problems with bacteriophages, though, is that t (Read more...)
Some procedures in which a needle is inserted deep into the body, such as epidurals, require the physician to have a steady hand and to know what to feel for. This is not easy to train for, as one needs real patients to really train on properly. Engineers at Penn State have now developed a […]
Circulating tumor cells (CTCs) are present in the blood of people suffering from most cancers, but because of their rarity their presence is very difficult to spot. A number of technologies have been developed in the past to capture and count CTCs (see flashbacks below), but they tend to still have a number of limitations. […]
SAN JOSE, Calif.–(BUSINESS WIRE)–IngenioSpec offers patent-protected smart eyewear technologies for seniors. As the elderly population continues to grow, technologies for aging will become crucial for ensuring seniors’ well-being. Existing devices and services attempt to address some of these needs, but can be unwieldy and conspicuous. IngenioSpec technology envisions a discreet, stylish product combining the ultimate in ease-of-use with compact, lightweight electronics in an item many senior
Series A funding of $11 million has been released to LensGen Inc. for further development of novel IOL technology intended to address presbyopia, according to a company press release.
A key clinical performance milestone triggered the release of funding as part of a $21 million funding series led by Hoya Group’s corporate investment arm, the release said.
In addition, LensGen, which is developing the “first modular, fluid-optic, curvature changing IOL,” received two broad and comprehensive patents from the U.S. Patent Office protecting its technology, the release said.